Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647266 | 0.85 | TSHR (0.38) | SMN1; SMN2TSHRELANE | |
| Ammonia Solution, Strong SCHEMBL31304789 | 0.82 | TSHR (0.36) | SMN1; SMN2TSHRELANE | |
| SCHEMBL3020915 | 0.81 | TP53 (0.36) | SMN1; SMN2TSHRCA14 | |
| SCHEMBL9764287 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2TSHR | |
| SCHEMBL19976145 | 0.77 | TP53 (0.33) | SMN1; SMN2 | |
| SCHEMBL12413027 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14 | |
| SCHEMBL984063 | 0.77 | TSHR (0.36) | SMN1; SMN2TSHR | |
| SCHEMBL2473035 | 0.76 | TSHR (0.32) | TSHRELANE | |
| SCHEMBL7601923 | 0.76 | TSHR (0.50) | SMN1; SMN2TSHRELANE | |
| SCHEMBL5986989 | 0.76 | TSHR (0.50) | SMN1; SMN2TSHRELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023134465-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8114949-B2 | (Meth)acrylate, polymer and resist composition | MITSUBISHI RAYON CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-2403481-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG | XenoPort, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010102252-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG | XENOPORT, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090226851-A1 | (METH)ACRYLATE, POLYMER AND RESIST COMPOSITION | MITSUBISHI RAYON CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | SMN1; SMN2 1079/4885TSHR 842/4885ELANE 1844/4885 |
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | ERG28, PDXK, PAH | SMN1; SMN2 3484/4885TSHR 4387/4885ELANE 1522/4885 |
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | ARG1, ASS1, ARG2 | SMN1; SMN2 2816/4885TSHR 2027/4885ELANE 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.